Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
19/05/2026 12:36
May 19 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA ANNOUNCES SUCCESSFUL OUTCOME OF FDA TYPE C MEETING REQUEST FOR HARMONIC™ PHASE 2 TRIAL OF LP-300 IN NEVER-SMOKERS WITH NSCLC LANTERN PHARMA INC - FDA RAISES NO OBJECTIONS TO KEY PROPOSED HARMONIC TRIAL AMENDMENTS LANTERN PHARMA INC - HARMONIC TRIAL TO FOCUS ENROLLMENT ON EGFR EXON 21 L858R MUTATION PATIENTS LANTERN PHARMA INC - HARMONIC TRIAL TO INCREASE MAXIMUM LP-300 TREATMENT CYCLES TO EIGHT LANTERN PHARMA INC - HARMONIC TRIAL TO DISCONTINUE CONTROL ARM OF THE HARMONIC TRIAL AND MIGRATE TO SINGLE-ARM DESIGN Source text: ID:nBwkdPPla Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview